Last C$0.66 CAD
Change Today +0.03 / 4.76%
Volume 58.7K
IMV On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 3:58 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

immunovaccine inc (IMV) Snapshot

Open
C$0.60
Previous Close
C$0.63
Day High
C$0.66
Day Low
C$0.60
52 Week High
02/7/14 - C$1.50
52 Week Low
08/1/13 - C$0.24
Market Cap
52.5M
Average Volume 10 Days
37.8K
EPS TTM
C$-0.07
Shares Outstanding
79.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOVACCINE INC (IMV)

Related News

No related news articles were found.

immunovaccine inc (IMV) Related Businessweek News

No Related Businessweek News Found

immunovaccine inc (IMV) Details

Immunovaccine Inc., a clinical-stage biopharmaceutical company, discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The company develops its products based on DepoVax vaccine-adjuvanting platform, a vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Its product candidates include DPX-Survivac, a therapeutic cancer vaccine, which has completed Phase I clinical trials for the treatment of ovarian and brain cancer; and DPX-0907, a therapeutic cancer vaccine that has completed Phase I clinical trials for the treatment of breast, ovarian, and prostate cancer. The company also develops pre-clinical stage vaccine product candidates for infectious diseases, including respiratory syncytial virus and anthrax. In addition, its product pipeline consists of DepoVax-validating partnered programs for addiction medicine and animal health. Immunovaccine Inc. was founded in 2000 and is headquartered in Halifax, Canada.

23 Employees
Last Reported Date: 05/28/14
Founded in 2000

immunovaccine inc (IMV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: C$200.0K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$128.8K
Compensation as of Fiscal Year 2013.

immunovaccine inc (IMV) Key Developments

ImmunoVaccine Inc. Presents at BIO International Convention, Jun-24-2014 02:00 PM

ImmunoVaccine Inc. Presents at BIO International Convention, Jun-24-2014 02:00 PM. Venue: San Diego Convention Center, San Diego, California, United States.

Immunovaccine Announces Management Changes

Immunovaccine Inc. announced that Marc Mansour, Ph.D., MBA, has been appointed as Chief Executive Officer. Albert Scardino, executive chairman since last year, will return to his role as non-executive chairman of the company. Dr. Mansour has previously served as the company's Chief Operating Officer and Chief Science Officer and is a member of its board of directors. Since joining Immunovaccine in 2001, Dr. Mansour has led the development of Immunovaccine's DepoVax(TM) platform and the Company's lead therapeutic cancer vaccine DPX-Survivac, which is being prepared for multiple Phase II clinical studies in 2014. During his recent tenure as COO, Dr. Mansour also spearheaded interactions with the investment community, as well as business development efforts.

Immunovaccine Inc. Announces Positive Clinical Data from Phase I/Ib Ovarian Cancer Study

Immunovaccine Inc. announced positive clinical data from Phase I/Ib clinical study with its cancer vaccine candidate, DPX-Survivac, in patients with ovarian cancer. Results presented from the Phase I/Ib clinical study demonstrate promising early evidence of clinical activity for DPX-Survivac in ovarian cancer patients, including one patient who experienced a partial response. The PR, defined as a shrinking of tumor size by at least 30%, using Response Evaluation Criteria In Solid Tumors (RECIST 1.1), was accompanied by reduction in levels of a commonly used ovarian cancer biomarker (CA125) and a significant increase in vaccine-induced immune responses. One study patient with residual disease following platinum therapy experienced a PR which correlated with robust immune responses to DPX-Survivac. The PR persisted following discontinuation of the treatment. Target immune responses were seen across all doses and when DPX-Survivac was administered alone or with low dose oral cyclophosphamide (CPA). Statistically significant increases in immune response were seen with higher doses of DPX-Survivac and when DPX-Survivac was combined with CPA. Results demonstrated that metronomic cyclophosphamide (mCPA), an immune modulating agent, enhanced the immunogenicity of DepoVax-based vaccines in preclinical cancer models consistent with previously reported phase I data showing a similar enhancement of DPX-Survivac in patients. Importantly, the animal studies demonstrated the combination therapy's ability to eliminate advanced tumors that could not be treated with vaccine or mCPA alone. The addition of anti-PD-1 checkpoint inhibitor to the DepoVax vaccine/mCPA combination resulted in further enhanced anti-tumor activity, which allowed the treatment of more advanced tumors. The effective tumor regressions that were observed could not be achieved without the use of vaccine or the use of anti-PD-1.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMV:CN C$0.66 CAD +0.03

IMV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMV.
View Industry Companies
 

Industry Analysis

IMV

Industry Average

Valuation IMV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 44.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOVACCINE INC, please visit www.imvaccine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.